Project Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Novel, subtype selective potentiators of nicotinic acetycholine receptors  

Nicotinic receptors have been implicated in a broad range of neurological disorders, including autism, and increasing the activation of nicotinic receptors could be beneficial to affected individuals. A molecule that regulates the receptor activity by binding to the receptor away from its active site, called an allosteric modulator, could lead to a new class of drugs to treat these disorders. This project explores a molecule with that potential, the natural product d-formylflustrabomide (dFBr). The interaction between dFBr and the nicotinic receptor will be characterized and dFBr will be used as a template to search for other molecules that may also specifically regulate nicotinic receptors. The goal of this study is to develop the natural product into a more usable form with increased potency and less potential side effects. Since this is a new type of drug, it may open up new avenues for understanding and treating autism spectrum disorders. Project Status


Funder National Institutes of Health
Fiscal Year Funding $325,757.00
Current Award Period 2009-2011
Project Number 5R01NS066059-02
Principal Investigator Schulte, Marvin
Received ARRA Funding? Yes
Strategic Plan Question Question 4: Which Treatments And Interventions Will Help? (Treatments)
Subcategory Model Systems/Therapeutic Targets
Strategic Plan Objective 4O. Not specific to Question 4 objectives
Federal or Private? Federal
Institution University of Alaska Fairbanks
State/Country Alaska
Web Link 1 Novel, subtype selective potentiators of nicotinic acetycholine receptors (External web link)
Web Link 2 No URL available.
Web Link 3 No URL available.
History/Related Projects Novel, subtype selective potentiators of nicotinic acetycholine receptors | $335,231.00 | 2009 | 1R01NS066059-01